169 related articles for article (PubMed ID: 15629613)
1. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein.
Sato S; Kajiyama Y; Sugano M; Iwanuma Y; Sonoue H; Matsumoto T; Sasai K; Tsurumaru M
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):203-11. PubMed ID: 15629613
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma.
Mimura K; Kono K; Hanawa M; Kanzaki M; Nakao A; Ooi A; Fujii H
Clin Cancer Res; 2005 Jul; 11(13):4898-904. PubMed ID: 16000588
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").
Fukutome M; Maebayashi K; Nasu S; Seki K; Mitsuhashi N
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):528-36. PubMed ID: 16965995
[TBL] [Abstract][Full Text] [Related]
4. Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab.
Voutsas IF; Mahaira LG; Fotopoulou K; Kapranos N; Reclos JG; Gritzapis AD; Papamichail M; Perez SA; Baxevanis CN
Int J Radiat Biol; 2013 May; 89(5):319-25. PubMed ID: 23311575
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
Gong SJ; Jin CJ; Rha SY; Chung HC
Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Lara PN; Chee KG; Longmate J; Ruel C; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Twardowski P; Doroshow JH; Gandara DR
Cancer; 2004 May; 100(10):2125-31. PubMed ID: 15139054
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
[TBL] [Abstract][Full Text] [Related]
8. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity.
Hsu C; Huang CL; Hsu HC; Lee PH; Wang SJ; Cheng AL
Cancer; 2002 Jan; 94(2):415-20. PubMed ID: 11900227
[TBL] [Abstract][Full Text] [Related]
10. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
[TBL] [Abstract][Full Text] [Related]
11. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
[TBL] [Abstract][Full Text] [Related]
12. ERBB2 amplifications in esophageal adenocarcinoma.
Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
[TBL] [Abstract][Full Text] [Related]
13. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
Carney WP
IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu.
Pratesi G; Petrangolini G; Tortoreto M; Addis A; Zunino F; Calcaterra C; Merlo A; Tagliabue E; Menard S; Balsari A
J Immunother; 2008; 31(6):537-44. PubMed ID: 18528301
[TBL] [Abstract][Full Text] [Related]
16. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
[TBL] [Abstract][Full Text] [Related]
18. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
[TBL] [Abstract][Full Text] [Related]
19. Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status.
Brodowicz T; Kandioler D; Tomek S; Ludwig C; Rudas M; Kunstfeld R; Koestler W; Hejna M; Budinsky A; Wiltschke C; Zielinski CC
Br J Cancer; 2001 Nov; 85(11):1764-70. PubMed ID: 11742500
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
Shoji M; Ninomiya I; Makino I; Kinoshita J; Nakamura K; Oyama K; Nakagawara H; Fujita H; Tajima H; Takamura H; Kitagawa H; Fushida S; Harada S; Fujimura T; Ohta T
Int J Oncol; 2012 Jun; 40(6):2140-6. PubMed ID: 22469995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]